


Humanized antibody ELISA binding assay on human PTK7



	2C5	2C8	13C4	cofetuzumab	Isotype
EC ₅₀ (nM)	0.0267	0.0317	0.0221	0.0729	NA

FIG. 1

Humanized antibody ELISA binding assay on cyno PTK7




FIG. 2

Humanized antibody ELISA binding assay on mouse PTK7




FIG. 3

Humanized antibody ELISA binding assay on rat PTK7





FIG. 4


Humanized antibody binding assay on PA-1 by FACS



	2C5	2C8	13C4	cofetuzumab	Isotype
EC ₅₀ (nM)	0.711	0.562	0.808	2.256	NA

FIG. 5


Humanized antibody binding assay on MDA-MB-468 by FACS



	2C5	2C8	13C4	cofetuzumab	Isotype
EC ₅₀ (nM)	0.543	0.481	0.558	1.987	NA

FIG. 6


Humanized antibody binding assay on MDA-MB-231 by FACS



	2C5	2C8	13C4	cofetuzumab	Isotype
EC ₅₀ (nM)	0.506	0.423	0.828	1.252	NA

FIG. 7

Humanized antibody binding assay on MDA-MB-463 by FACS



	2C5	2C8	13C4	cofetuzumab	Isotype
EC ₅₀ (nM)	0.488	0.339	0.623	1.440	NA

FIG. 8

6/36




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24





FIG. 25



	2C5-LD110(8)	2C8-LD110(8)	13C4-LD110(8)	cofetuzumab-LD110(8)	b12-LD110(8)
IC ₅₀ (nM)	0.034	~ 3.492e-008	~ 1.749e-008	~ 5.321e-011	8.791

FIG. 26




FIG. 27






FIG. 28



	2C5-LD110(8)	2C8-LD110(8)	13C4-LD110(8)	cofetuzumab-LD110(8)	b12-LD110(8)
IC ₅₀ (nM)	~ 5.046e-005	~ 0.0004539	0.888	0.632	33.480

FIG. 29



	2C5-LD038(8)	2C8-LD038(8)	13C4-LD038(8)	cofetuzumab-LD038(8)	b12-LD038(8)
IC ₅₀ (nM)	~ 5.046e-005	~ 0.0004539	0.888	0.203	33.480

FIG. 30

***In Vitro* Cell Cytotoxicity on MDA-MB-468**
(1500 cells/well) 96h




FIG. 31

***In Vitro* Cell Cytotoxicity on OVCAR-3**
(1500 cells/well) 96h




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36

20/36

***In Vitro* Cell Cytotoxicity on NCI-H292**
(1500 cells/well) 96h




FIG. 37

***In Vitro* Cell Cytotoxicity on NCI-H520**
(1500 cells/well) 96h




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42

23/36




FIG. 43




FIG. 44

24/36

PA-1




FIG. 45

OVCAR-3




FIG. 46




FIG. 47




FIG. 48

26/36

SW780




FIG. 49

RT4




FIG. 50

27/36

AGS




FIG. 51

KYSE-150




FIG. 52

28/36




FIG. 53




FIG. 54A




FIG. 54B




FIG. 55




FIG. 56




FIG. 57

32/36




FIG. 58




FIG. 59

33/36




FIG. 60




FIG. 61




FIG. 62A




FIG. 62B




FIG. 62C




FIG. 63




FIG. 64